Nang Kuang Pharmaceutical Third Quarter 2024 Earnings: EPS: NT$0.58 (vs NT$0.46 in 3Q 2023)
Nang Kuang Pharmaceutical (TWSE:1752) Third Quarter 2024 Results
Key Financial Results
- Revenue: NT$579.9m (up 8.0% from 3Q 2023).
- Net income: NT$58.1m (up 25% from 3Q 2023).
- Profit margin: 10.0% (up from 8.7% in 3Q 2023).
- EPS: NT$0.58 (up from NT$0.46 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nang Kuang Pharmaceutical shares are down 3.3% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Nang Kuang Pharmaceutical (1 shouldn't be ignored) you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Nang Kuang Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TWSE:1752
Nang Kuang Pharmaceutical
Engages in the manufacturing, processing, trading, import, and export of pharmaceuticals and medical devices in Taiwan and internationally.
Excellent balance sheet second-rate dividend payer.
